Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
437 hedge funds and large institutions have $21.8B invested in Alexion Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 148 increasing their positions, 181 reducing their positions, and 29 closing their positions.
117% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 29
54% more call options, than puts
Call options by funds: $249M | Put options by funds: $162M
26% more capital invested
Capital invested by funds: $17.3B → $21.8B (+$4.51B)
8% more funds holding
Funds holding: 406 → 437 (+31)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
18% less repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 181
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$346M |
| 2 |
JP Morgan Chase
New York
|
+$145M |
| 3 |
YCMGA
York Capital Management Global Advisors
New York
|
+$120M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$86.7M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$85.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$229M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$156M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$153M |
| 4 |
Jennison Associates
New York
|
-$112M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$97M |
ALXN Hedge Fund Activity: Q3 2013 in Review
437 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2013, worth a combined $21.8B — up 26% from $17.3B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new ALXN positions and 29 closed out — a net gain of 34 holders — while 148 added to existing stakes and 181 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $346M. The largest seller was Viking Global Investors, cutting an estimated $229M.
- 437 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2013, up from 406 in Q2 2013.
- Funds reported $21.8B of Alexion Pharmaceuticals stock for Q3 2013, up 26% quarter-over-quarter.
- 63 funds opened new Alexion Pharmaceuticals positions in Q3 2013 and 29 closed out, a net change of +34 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $346M added.
- The largest Alexion Pharmaceuticals seller in Q3 2013 was Viking Global Investors, an estimated $229M sold.
Based on aggregated 13F filings for Q3 2013.